These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 34221866)

  • 21. Enasidenib: An Oral IDH2 Inhibitor for the Treatment of Acute Myeloid Leukemia.
    Myers RA; Wirth S; Williams S; Kiel PJ
    J Adv Pract Oncol; 2018; 9(4):435-440. PubMed ID: 30719396
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure-Based Drug Design of Novel Triaminotriazine Derivatives as Orally Bioavailable IDH2
    Wei Q; Yao K; Yang J; Zhou Q; Liu P; Chen J; Liu H; Lai Y; Cao P
    J Med Chem; 2023 Sep; 66(18):12894-12910. PubMed ID: 37706660
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics.
    Golub D; Iyengar N; Dogra S; Wong T; Bready D; Tang K; Modrek AS; Placantonakis DG
    Front Oncol; 2019; 9():417. PubMed ID: 31165048
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical absorption, distribution, metabolism, excretion and pharmacokinetics of a novel selective inhibitor of breast cancer resistance protein (BCRP).
    Liao M; Chuang BC; Zhu Q; Li Y; Guan E; Yu S; Yang J; Prakash S; Xia CQ
    Xenobiotica; 2018 May; 48(5):467-477. PubMed ID: 28485193
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitation of isocitrate dehydrogenase (IDH)-induced D and L enantiomers of 2-hydroxyglutaric acid in biological fluids by a fully validated liquid tandem mass spectrometry method, suitable for clinical applications.
    Poinsignon V; Mercier L; Nakabayashi K; David MD; Lalli A; Penard-Lacronique V; Quivoron C; Saada V; De Botton S; Broutin S; Paci A
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jun; 1022():290-297. PubMed ID: 27131892
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors.
    Fan B; Mellinghoff IK; Wen PY; Lowery MA; Goyal L; Tap WD; Pandya SS; Manyak E; Jiang L; Liu G; Nimkar T; Gliser C; Prahl Judge M; Agresta S; Yang H; Dai D
    Invest New Drugs; 2020 Apr; 38(2):433-444. PubMed ID: 31028664
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Understanding
    B Shekhawat P; B Pokharkar V
    Acta Pharm Sin B; 2017 May; 7(3):260-280. PubMed ID: 28540164
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assays.
    Urban DJ; Martinez NJ; Davis MI; Brimacombe KR; Cheff DM; Lee TD; Henderson MJ; Titus SA; Pragani R; Rohde JM; Liu L; Fang Y; Karavadhi S; Shah P; Lee OW; Wang A; McIver A; Zheng H; Wang X; Xu X; Jadhav A; Simeonov A; Shen M; Boxer MB; Hall MD
    Sci Rep; 2017 Oct; 7(1):12758. PubMed ID: 28986582
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma.
    Konteatis Z; Artin E; Nicolay B; Straley K; Padyana AK; Jin L; Chen Y; Narayaraswamy R; Tong S; Wang F; Zhou D; Cui D; Cai Z; Luo Z; Fang C; Tang H; Lv X; Nagaraja R; Yang H; Su SM; Sui Z; Dang L; Yen K; Popovici-Muller J; Codega P; Campos C; Mellinghoff IK; Biller SA
    ACS Med Chem Lett; 2020 Feb; 11(2):101-107. PubMed ID: 32071674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety Profile of Ivosidenib in the Management of Patients with Acute Myeloid Leukemia (AML): An Update on the Emerging Evidence.
    Stemer G; Rowe JM; Ofran Y
    Blood Lymphat Cancer; 2021; 11():41-54. PubMed ID: 34188585
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High degree of pharmacokinetic compatibility exists between the five-herb medicine XueBiJing and antibiotics comedicated in sepsis care.
    Li J; Olaleye OE; Yu X; Jia W; Yang J; Lu C; Liu S; Yu J; Duan X; Wang Y; Dong K; He R; Cheng C; Li C
    Acta Pharm Sin B; 2019 Sep; 9(5):1035-1049. PubMed ID: 31649852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thyroiditis: A Rare Manifestation of Enasidenib-Induced Differentiation Syndrome.
    Annamaraju P; Gopishetty S; Goparaju N; Beasey M; Kota V; Guddati AK
    Case Rep Oncol; 2020; 13(2):583-587. PubMed ID: 32547385
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IDH1/IDH2 Inhibition in Acute Myeloid Leukemia.
    Cerchione C; Romano A; Daver N; DiNardo C; Jabbour EJ; Konopleva M; Ravandi-Kashani F; Kadia T; Martelli MP; Isidori A; Martinelli G; Kantarjian H
    Front Oncol; 2021; 11():639387. PubMed ID: 33898313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [IDH mutations activate Hoxa9/Meis1 and hypoxia pathways in acute myeloid leukemia model mice].
    Ogawara Y; Kitabayashi I
    Rinsho Ketsueki; 2015 Aug; 56(8):1045-52. PubMed ID: 26345565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Isocitrate dehydrogenase mutations in myeloid malignancies.
    Medeiros BC; Fathi AT; DiNardo CD; Pollyea DA; Chan SM; Swords R
    Leukemia; 2017 Feb; 31(2):272-281. PubMed ID: 27721426
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enasidenib in the treatment of relapsed/refractory acute myeloid leukemia: an evidence-based review of its place in therapy.
    Galkin M; Jonas BA
    Core Evid; 2019; 14():3-17. PubMed ID: 31118877
    [No Abstract]   [Full Text] [Related]  

  • 37. Ivosidenib to treat adult patients with relapsed or refractory acute myeloid leukemia.
    Pasquier F; Lecuit M; Broutin S; Saada S; Jeanson A; Penard-Lacronique V; de Botton S
    Drugs Today (Barc); 2020 Jan; 56(1):21-32. PubMed ID: 32055803
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
    Perl AE; Altman JK; Cortes J; Smith C; Litzow M; Baer MR; Claxton D; Erba HP; Gill S; Goldberg S; Jurcic JG; Larson RA; Liu C; Ritchie E; Schiller G; Spira AI; Strickland SA; Tibes R; Ustun C; Wang ES; Stuart R; Röllig C; Neubauer A; Martinelli G; Bahceci E; Levis M
    Lancet Oncol; 2017 Aug; 18(8):1061-1075. PubMed ID: 28645776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
    Pituch-Noworolska A
    Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.